Transplant News and Research

RSS

Chronic kidney disease patients with depression have poorer health outcomes: Researchers

Patients with chronic kidney disease who have been diagnosed with depression are twice as likely to be hospitalized, progress to long-term dialysis treatments or die within a year as those who are not depressed, UT Southwestern Medical Center researchers have found.

20 May 2010

Adult, pediatric critical care and progressive care units named recipients of 2010 Beacon Award for Excellence

The American Association of Critical-Care Nurses recently named 73 units — including 60 adult, four pediatric critical care and nine progressive care units — nationwide recipients of the spring 2010 Beacon Award for Excellence.

20 May 2010

ABBOTT PRISM Chagas test receives FDA approval

Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug."

19 May 2010

Early tracheotomy not beneficial in terms of MV duration, mortality compared to late tracheotomy

Early tracheotomy in ICU patients on mechanical ventilation (MV) did not reduce mortality when compared to later tracheotomy in a study of cardiac surgery patients requiring prolonged ventilation in a Paris study.

19 May 2010

Where are Australia’s missing hepatitis C cases?

Around 90% of those infected have not received treatment, despite the potential for cure, a report to coincide with National Hepatitis Week shows

18 May 2010

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells administered intravenously can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury, according to research from the University of California San Francisco.

18 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

Researchers treat undiagnosed FIM with experimental stem cell transplant

Researchers at the Queensland Institute of Medical Research and the Royal Brisbane Women's Hospital have identified a previously undiagnosed condition and successfully treated it by performing an experimental stem cell transplant.

18 May 2010

FDA accepts for filing Sigma-Tau Pharmaceuticals' cysteamine hydrochloride ophthalmic solution NDA

Sigma-Tau Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the company's new drug application (NDA) for its cysteamine hydrochloride ophthalmic solution, an investigational therapy for the treatment of corneal cystine crystals in patients with cystinosis. The FDA also granted the NDA Priority Review status, a designation given to drugs that may provide major advances or a treatment where no adequate therapy exists.

18 May 2010

Australian doctors identify new disease and devise its cure

A team of Australian doctors have identified a new disease and its cure. In their report published in the journal Clinical Infectious Diseases the doctors from The Queensland Institute of Medical Research (QIMR) report a case of a young NSW woman ill for almost a decade with repeated hospitalizations. She is now said to be suffering from a diseases that disabled the signaling processes of her immune system. The diseases is not named yet. Dr Maher Gandhi, head of QIMR's Immunohemotology Laboratory believes there are more cases of this disease. He said this Monday, “I haven't got a name for it other than T-cell signaling defect of which I assume there are quite a few different types… There are no recorded cases of this in the literature. Katie is unique ... I think we're at the tip of the iceberg here.”

17 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

17 May 2010

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

Saint John's Health Center Trustee and philanthropist Patrick Soon-Shiong, M.D., who developed the first FDA-approved protein nanoparticle treatment for cancer, has received the 2010 Distinguished Medical Science Award from the Friends of the National Library of Medicine for his significant contributions to the research and treatment of diabetes and cancer.

15 May 2010

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

SANUWAVE Health, Inc.,, an emerging medical technology company focused on regenerative medicine, today reported financial results for the three months ended March 31, 2010 and provided a business update.

14 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

Study evaluates cost-utility of MARS treatment in ALF patients

Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account.

13 May 2010

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Clinical Data, Inc., announced today that its PGxHealth division is expanding its FAMILION family of genetic tests to include two new tests to diagnose heart diseases. With the launch of a test for Conduction Disease associated with Dilated Cardiomyopathy and a test for Short QT Syndrome, PGxHealth continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases.

12 May 2010

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

NY public hospital system plans to lay off about 500 workers and other state news

The Wall Street Journal: "New York City's Health & Hospitals Corp., the nation's largest public hospital system, plans to stanch a $1.2 billion budget gap in the next year's budget by laying off about 500 workers and ending contracts with 'a significant number' of physicians, its president said.

12 May 2010

DUSA Pharmaceuticals first-quarter total product revenues up 22%

DUSA Pharmaceuticals, Inc., a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010.

11 May 2010

Transplant News and Research

Chronic kidney disease patients with depression have poorer health outcomes: Researchers

Adult, pediatric critical care and progressive care units named recipients of 2010 Beacon Award for Excellence

ABBOTT PRISM Chagas test receives FDA approval

Early tracheotomy not beneficial in terms of MV duration, mortality compared to late tracheotomy

Where are Australia’s missing hepatitis C cases?

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

Researchers treat undiagnosed FIM with experimental stem cell transplant

FDA accepts for filing Sigma-Tau Pharmaceuticals' cysteamine hydrochloride ophthalmic solution NDA

Australian doctors identify new disease and devise its cure

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

Chimerix commences first-in-human study of CMX157 for HIV

Study evaluates cost-utility of MARS treatment in ALF patients

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

NY public hospital system plans to lay off about 500 workers and other state news

DUSA Pharmaceuticals first-quarter total product revenues up 22%

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News